Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial

• Published in: BMC medicine 2023-11, Vol.21 (1), p.1-423, Article 423
• Main Authors: Fang, Yu, Su, Ning, Zou, Qihua, Cao, Yi, Xia, Yi, Tang, Linquan, Tian, Xiaopeng, Liu, Panpan, Cai, Qingqing
• Format: Article
• Language: English
• Subjects: Analysis; Angiogenesis inhibitors; Anlotinib; Antiangiogenic therapy; Anticancer properties; Antimitotic agents; Antineoplastic agents; Antitumor agents; Cancer; Cancer therapies; Carcinoma; Care and treatment; Clinical trials; Development and progression; Disease control; Dosage and administration; Health services; Hemorrhage; Hypertension; Immunotherapy; Kinases; Medical prognosis; Metastases; Metastasis; Metastatic; Mucositis; Nasopharyngeal cancer; Nasopharyngeal carcinoma; Patients; Prevention; Product development; Protein-tyrosine kinase; Recurrent; Relapse; Risk factors; Survival; Throat cancer; Toxicity; Triglycerides; Tyrosine; Vascular endothelial growth factor
• ISSN: 1741-7015; 1741-7015
• DOI: 10.1186/s12916-023-03140-x

Background Treatment options beyond the first-line setting for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) are limited. The role of the multitarget tyrosine kinase inhibitor anlotinib in RM-NPC is unclear. Methods In this prospective, single-arm, phase 2 trial, patients with histologically confirmed RM-NPC and failure of at least two lines of prior systemic treatments were eligible. Anlotinib was given at 12 mg once daily on days 1-14 every 3 weeks until disease progression or intolerable toxicities. The primary end point was disease control rate, defined as the percentage of patients achieving complete response, partial response, or stable disease by RECIST criteria. Results From April 2019 to March 2021, 39 patients were enrolled and received a median of 4 cycles (range, 0.5-20) of anlotinib treatment. Partial response and stable disease were observed in 8 and 20 patients, respectively. The disease control rate was 71.8%, and objective response rate was 20.5%. With a median follow-up of 17.2 months, the median progression-free survival was 5.7 months. The 12-month overall survival was 58.3%, and the median overall survival was not reached. The most frequent grade 3/4 treatment-related adverse events were hand-foot syndrome (23.7%), oral mucositis (21.0%), hypertension (7.9%), and triglyceride elevation (7.9%). Hemorrhage, all grade 1 or 2, occurred in 34.2% of the patients. Conclusions Anlotinib monotherapy exhibited promising anti-tumor activities and disease control for heavily pretreated RM-NPC patients with a tolerable toxicity profile. Trial registration ClinicalTrials.gov: NCT03906058. Keywords: Anlotinib, Nasopharyngeal carcinoma, Recurrent, Metastatic, Antiangiogenic therapy